The Valens Company Granted License To Conduct Human Trials

A huge win for The Valens Company and the development of new beverage and edible products.

The Valens Company Inc. (TSX: VLNS) a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, today announced that it has received its Cannabis Research License under Health Canada's Cannabis Act and Cannabis Regulations through its wholly-owned subsidiary, Valens Agritech Ltd.

This license permits The Valens Company to conduct research involving the administration or distribution of cannabis to human subjects for the assessment of taste, sight, smell or touch, subject to conditions laid out by Health Canada. The Company will use this license to conduct controlled human trials for the sensory evaluation of its cannabis extracts, concentrates and oils, including vaporizers, and beverage and edible products, at its extraction, manufacturing and testing facilities in Kelowna, B.C.

This exciting and strategic milestone gives us the competitive advantage to further innovate and differentiate our leading oil-based product offerings Tyler Robson, Chief Executive Officer of The Valens Company.

Mr Robson went on to say that "With this research license, we are now able to perform sensory assessments at the product development stage to determine quality and marketability of our products to maximize potential launch success. Findings from future proprietary research initiatives will advance our understanding of cannabis preferences allowing us to continue developing premium, next generation products that meet evolving customer and consumer needs."

Sensory evaluation measures, analyses, and interprets the reactions of human subjects to products as perceived by the senses, and is used as a way of determining whether product differences are detected, the basis for those differences and the diversity of preferences. This evaluation method will enhance the Company's custom manufacturing and white label services with the added ability to assess the palatability of bespoke cannabis blends formulated with Valens' extensive terpene database. It will also expand the Company's innovation pipeline across all key product divisions.

Jeff Fallows, President of The Valens Company, added, "Cannabis research derived from human trials is highly critical and valuable at this stage of the industry's growth cycle, and we look forward to having data-backed knowledge of how consumers experience different products to advance our research and development strategy, and in turn, bring consumer focused products to market. This research license not only solidifies our position as a one-stop shop for our customers by increasing our presence within their value chains, but also provides added credibility to our platform as we look to expand to new markets."

To follow the latest developments on the Cannabis industry click here

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Mark Page
Mark Page

Mark is a UK born investing enthusiast based in Sydney. He has a keen eye for technical analysis and is paying close attention to the ongoing legalisation of cannabis for the health benefits, opportunities, and emergent industries that will follow.

Leave a Reply

Your email address will not be published. Required fields are marked *